(4AR,10AR)-1-丙基-2,3,10,10A-四氢-1H,4AH-4,9-二氧杂-1-氮杂菲-6-醇盐酸盐 | 300576-59-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: (4AR,10AR)-1-丙基-2,3,10,10A-四氢-1H,4AH-4,9-二氧杂-1-氮杂菲-6-醇盐酸盐
• 中文别名: (+)-PD128907,盐酸盐；(+)-PD 128907, 盐酸盐
• 英文名称: (4aR,10bR)-rel-4-Propyl-2,3,4,4a,5,10b-hexahydrochromeno[4,3-b][1,4]oxazin-9-ol hydrochloride
• 英文别名: (4aR,10bR)-4-propyl-3,4a,5,10b-tetrahydro-2H-chromeno[4,3-b][1,4]oxazin-9-ol;hydrochloride
• CAS: 300576-59-4
• 化学式: C14H20ClNO3
• 分子量: 285.76
• InChiKey: DCFXOTRONMKUJB-QMDUSEKHSA-N

物化性质

• 溶解度：
  乙醇：>10mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.36
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  41.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (+)-(4aR,10bR)-3,4,4a,10b-tetrahydro-9-methoxy-4-propyl-2H,5H-<1>benzopyrano<4,3-b>-1,4-oxazine hydrochloride 、 二氯甲烷 、 三溴化硼 、 ammonium hydroxide 以73%的产率得到
  参考文献：
  名称：

  DIJKSTRA, DURK;MULDER, THEO B. A.;ROLLEMA, HANS;TEPPER, PIETER G.;VAN, DE+, J. MED. CHEM., 31,(1988) N 11, C. 2178-2182

  摘要：

  DOI：

文献信息

• D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
  申请人：DREXEL UNIVERSITY

  公开号：US10543180B2

  公开（公告）日：2020-01-28

  The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.

  本发明提供了一种抑制、抑制或预防帕金森病患者左旋多巴诱发的运动障碍的方法，包括向患者施用包含至少一种本发明化合物的药物组合物的步骤。本发明进一步提供了一种抑制、抑制或预防患者帕金森病的方法，包括向患者施用包含至少一种本发明化合物的药物组合物的步骤。
• Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease
  申请人：University of Medicine and Dentistry New Jersey Medical School

  公开号：US20140228380A1

  公开（公告）日：2014-08-14

  The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
• NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE
  申请人：DREXEL UNIVERSITY

  公开号：US20170246128A1

  公开（公告）日：2017-08-31

  The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
• US9675565B2
  申请人：——

  公开号：US9675565B2

  公开（公告）日：2017-06-13